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Estes NAM III, Halperin JL, Calkins H, et al. ACC/AHA/Physician Consortium 2008 Clinical Performance
Measures for Adults With Nonvalvular Atrial Fibrillation or Atrial Flutter. J Am Coll Cardiol 2008;51:865–84;
http://dx.doi.org/10.1016/j.jacc.2008.01.006.
Implementation Notes (version 1.0) describing important changes to 2 of the measures included in this article are available
on the American College of Cardiology (cardiosource.org) and American Heart Association, Inc. (my.americanheart.org)
Web sites. The revisions detailed in “Implementation Notes 1.0 for the ACC/AHA/Physician Consortium 2008 Clinical
Performance Measures for Adults With Nonvalvular Atrial Fibrillation or Atrial Flutter” are meant to clarify the measures
and were agreed on as part of the review process for endorsement by the National Quality Forum’s Cardiovascular
Endorsement and Maintenance Steering Committee.
In general, the revisions are intended 1) to clarify that the CHADS2 (Cardiac Failure, Hypertension, Age, Diabetes,
troke [Doubled]) risk classification scheme was used in constructing these measures and 2) to acknowledge newer U.S. Food
nd Drug Administration–approved oral anticoagulant drugs (other than warfarin) that are now available to prevent
hromboembolism in patients with atrial fibrillation.
“Measure 1. Assessment of Thromboembolic Risk Factors” (Appendix C, p. 876) and “Measure 2. Chronic Anticoag-
lation Therapy” (Appendix C, p. 878) should be replaced by the revised measure specifications in the online Implementation
otes 1.0, which are available at: http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-
tandards.aspx.
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